natgillin/translations-raw huggingface dataset:
A composition for the removal of biofilm formed by Staphylococcus aureus containing bacteriophage capable of killing Staphylococcus aureus specifically and effective in destroying biofilm formed by Staphylococcus oureus as an active ingredient, wherein the bacteriophage is the Myoviridae family T4-like phage genus bacteriophage designated bacteriophage SAP-1 and deposited at the Korean Collection for Type Cultures on July 10, 2007 under the Accession No: KCTC 11153BP or the Podoviridoe family ϕ29-like virus genus bacteriophage designated bacteriophage SAP-2 and deposited at the Korean Collection for Type Cultures on July 10, 2007 under the Accession No: KCTC 11154BP. 
HR P20160038 T1 PATENTNI ZAHTJEVI nana Sastav za uklanjanje biofilma stvorenog od Staphylococcus aureusa koji kao aktivni sastojak sadrži bakteriofag sposoban za specifično ubijanje Staphylococcus aureusa 1 učinkovit za uništavanje biofilma stvorenog od Staphylococcus aureusa, pri čemu je bakteriofag 1z obitelji Myoviridae, sličan fagu roda T4 bakteriofaga usmjereni bakteriofag SAP-I i pohranjen u Korejskoj zbirci za uzorke kultura 10. srpnja 2007. godine s pristupnim brojem:
A compound of the formula 
Spoj formule IIa:
A pharmaceutical composition comprising an effective amount of a compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof. 
16. Farmaceutski sastav koji sadrži učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva od 1 do 14.ili njegovu
Microcarriers are small solid particles on which cells may be grown in suspension culture. 
Mikronosači su male čvrste čestice na kojima stanice mogu rasti u suspenzijskom uzgoju.
The firearm support according to claim 1, wherein the support element comprises a lateral bracket, for being coupled to a side of the firearm. 
Nosač vatrenog oružja prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu potporni element (108) sadrži bočni držač (118), za spajanje sa stranom vatrenog oružja (10).
In yet another aspect, embodiments of the present invention encompass methods for manufacturing a hemostatic sponge which may include providing a sponge having a matrix of a biomaterial in dried form, providing a reactive polymeric material in the form of a solution, contacting the sponge or biomaterial and the polymeric material so that the sponge or biomaterial is impregnated with the polymeric material, and drying the impregnated biomaterial. Exemplary embodiments further encompass sponges obtainable by the manufacturing methods described herein. 
Postupak za proizvodnju hemostatske porozne kompozitne spužve naznačen time da se sastoji od a) osiguravanja porozne spužve koja sadrži matricu biomaterijala u suhom obliku, b) osiguravanja jedne hidrofilne polimerne komponente koja sadrži elektrofilne reaktivne skupine u obliku otopine, pri čemu navedeni jedan reaktivni polimerni materijal je hidrofilno sredstvo za umrežavanje, c) -kontaktiranje a) i b) tako da je materijal iz a) impregniran s b), i d) sušenje materijala dobivenog u koraku c).
A method for synthesizing a protein or peptide in vivo, said method comprising introducing an RNA molecule as recited in claim 8 into cells, wherein the RNA molecule comprises an open reading frame, under conditions conducive to translating the open reading frame of the RNA molecule into the protein or peptide encoded by the open reading frame. 
Metoda za sintetiziranje proteina ili peptida in vitro, navedena metoda sadrži uvođenje molekule RNA nabrojene u patentnom zahtjevu 8 u stanice, pri čemu molekula RNA sadrži otvoreni okvir čitanja, pod uvjetima povoljnim za translaciju otvorenog okvira čitanja molekule RNA u protem 1li peptid kodiran otvorenim okvirom čitanja.
General Description of Compounds of the Invention 
Datum objave europske prijave patenta:
Analytical LC-MS data were obtained on a PE Sciex API 150EX instrument equipped with IonSpray source and Shimadzu LC-8A/SLC-10A LC system. 
Analitički i C-MS podaci dobiveni su na instrumentu PE Sciest API 150EX opremljenom IonSpray izvorom i sustavu Shimadzu LC-BA/SLC-10A LC.
A capsule according to any one of the preceding claims, wherein the projection is made of the same material as the cup. 
Sistem prema bilo kojem od patentnih zahtjeva 2-14, naznačen time da su ispusti (28.i) napravljeni od plastičnih materijala.
A virion or virus particle comprising a recombinant adeno-associated viral (rAAV) vector comprising at least a first polynucleotide that comprises a photoreceptor-specific human rhodopsin kinase promoter-operably linked to at least a first nucleic acid segment that encodes at least a first biologically-active, retinal-specific human guanylate cyclase polypeptide that comprises at least a first contiguous amino acid sequence region that is at least about 95% identical to an at least 120 contiguous amino acid sequence from SEQ ID NO:1, wherein the rAAV vector is a recombinant adeno-associated virus serotype 5 (rAAV5) vector or wherein the rAAV vector is a recombinant adeno-associated virus serotype 8 (rAAV8) vector. 
HR P20190144 T1 PATENTNI ZAHTJEVI Rekombinantni adeno-povezani virusni (rAAV) vektor koji sadrži barem prvi polinukleotid koji sadrži promotor fotoreceptorski specifične ljudske rodopsin kinaze koji je operativno povezan barem na prvi segment nukleinske kiseline koji kodira barem prvi biološki aktivan, polipeptid fotoreceptorski specifične ljudske gvanilat ciklaze koji sadrži barem prvu susjednu regiju sekvence aminokiseline koja je barem oko 95% identična s najmanje 120 susjednih sekvenci aminokiseline iz SEQ ID NO:1, pri čemu rAAV vektor je vektor rekombinantnog adenopovezanog virusa serotip 5 (TAAVS) ili pri čemu rAAV vektor je vektor rekombinantnog adeno-povezanog virusa serotip 8 (rAAV8).
The construction kit for chocolate or chocolate-like products according to claim 7, wherein in said method the cocoa pulp and mucilage obtained in the depulping step is processed separately from the unfermented cocoa beans and subsequently added to the suspension before or during steps (a), (b), (c) or (d). 
Komplet za proizvodnju čokolade ili čokoladi sličnih proizvoda u skladu s patentnim zahtjevom 5, naznačen time što se u navedenom postupku kakaovu pulpu i biljnu sluz dobivene u koraku depulpiranja obradi odvojeno od nefermentiranih zrna kakaa, te naknadno doda u suspenziju prije ili tijekom koraka (a), (b), (c) ili (d).
The method of claim 15, wherein the double stranded RNAi agent is to be administered subcutaneously or intravenously. 
RNAi sredstvo ili farmaceutski pripravak za uporabu prema zahtjevu 15, naznačeno time da se dvolančano RNA1 sredstvo treba davati potkožno ili intravenozno.
The use of claim 1, wherein the cognitive disorders and diseases associated with the RyR are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Spoj prema patentnom zahtjevu 11, naznačen time što su kognitivni poremećaji 1 bolesti izabrani iz grupe koju čine Alzhajmerova bolest, oblici gubitka pamćenja i gubitak pamćenja ovisan od starenja.
when the transformation block information indicates existence of the at least one significant coefficient, obtaining, from a bitstream, an x index indicating an x coordinate of a last significant coefficient, from among the transformation coefficients of the transformation block, and a y index indicating a y coordinate of the last significant coefficient; 
Postupak entropijskog dekodiranja koeficijenata transformacije, te postupak sadrži: dobivanje, iz toka bitova, indikator kodiranog bloka koji pokazuje da li u transformacijskom bloku postoji najmanje jedan značajni koeficijent transformacije koji ima vrijednost različitu od nula;
Additionally, talc silicified can be also comprised in the dry powder preparation of the present invention in an amount of 2 mg per 100 mg of dry powder preparation. 
Dodatno, pripravak suhog praha predmetnog izuma može također sadržavati silificirani talk u količini od 2 mg po 100 mg pripravka suhog praha.
In a further aspect, the invention provides an inhalation device, or a pack of two or more inhalation devices, containing a medicament or pharmaceutical composition as herein before described in inhalable form as herein before described. 
U daljnjem aspektu, izum daje napravu za mnhaliranje, ili pakiranje od dvije ili više naprava za inhaliranje, koje sadrže lijek ili farmaceutski sastav, kako je ovdje prije opisano, u obliku koji se može inhalirati, kako je ovdje prije opisano.
the method further comprising exchanging sulfonic acid group protons of the sPEEK for cations. 
Metoda u skladu sa zahtjevom 12, naznačena time što nadalje obuhvaća zamjenu protona skupine sulfonske kiseline sPEEK-a za katione.
reacting a compound of formula II with a compound of formula IIa to provide a compound of formula I′. 
(vi) reakciju spoja formule II sa spojem formule II, kako bi se dobilo spoj formule I:
Container as claimed in one of the preceding claims, characterized in that the pre-cut part (6) comprises the handle for easily opening the wall section (4). 
Spremnik (1) prema jednom od prethodnih patentnih zahtjeva, naznačen time da prethodno odrezani dio (6) ima držač za lagano otvaranje dijela stijenke (4) koje graniči s dijelom stijenke (4).
Use of 2-((1-methylpropyl)amino)ethanol as an additive in an aqueous suspension, containing from 25 to 62 vol. %, based on the total volume of the suspension, of at least one calcium carbonate-comprising material and having a pH of between 8.5 and 11, for increasing the suspension pH by at least 0.3 pH units, wherein the suspension conductivity change is not more than 100 µS/cm per pH unit, characterized in that said 2-((1-methylpropyl)amino)ethanol is added to said suspension in an amount of from 500 to 15000 mg, per liter of the aqueous phase of said suspension. 
Postupak povećavanja pH vodene suspenzije koja sadrži 25 do 62 vol.% barem jednog materijala s kalcijevim karbonatom i ima pH između 8,5 1 11, naznačen time da postupak uključuje korak dodavanja 2-((1- metilpropil)amino)etanola u suspenziju u količini za povećanje pH otopine za najmanje 0,3 pH jedinice, pri čemu promjena vodljivosti otopine nije veća od 100 uS/em po jedinici pH, naznačen time da je navedeni 2-((1- metilpropil)amino)etanol dodan u navedenu otopinu u količini od 500 do 15000 mg, po litri vodene faze navedene otopine.
wherein R6, R7, R8 and X have the meanings assigned to them in claim 1, and Ar is an optionally substituted phenyl group with an aryl boronic acid of the Formula (AA) 
Formula (2) gdje R% R', RÅ i X imaju značenja koja su im naznačena u zahtjevu 1, a Ar je opcijski supstituirana fenilna skupina sa aril boronskom kiselinom formule (AA) ni
The capsule of claim 6 wherein the time delay agent is one of sodium alginate, glyceryl monostearate, glyceryl distearate, acrylic acids, celluloses or combinations thereof. The capsule of claim 1 wherein 
Kapsula u skladu s patentnim zahtjevom 6, naznačena time što se tvar koja odgađa otpuštanje sastoji od natrijeva alginata, gliceril monostearata, gliceril distearata, akrilnih kiselina, celuloza ili kombinacija navedenog.
reacting a compound of formula VII with a compound of formula IV (or an amino-protected form thereof) wherein R1, R2 and R3 have the meaning described in claim 1, followed if necessary by the removal of any protecting group that may be present; or 
HNR2R3 VII IV pri čemu Ri, R2 i R3 imaju značenje kako je opisano u patentnom zahtjevu 1, nakon čega po potrebi slijedi uklanjanje bilo koje zaštitne skupine koja može biti nazočna; ili
The power-generating system of claim 7, wherein at least one cable is made of a material selected from the group consisting of steel, wire rope, aramid fibers, liquid crystal polymer fibers, ultra-high-molecular-weight polyethylene fibers. 
Sustav (10) za generiranje snage prema Zahtjevu 7, gdje je najmanje jedan kabel izrađen od materijala izabranog iz grupe koja sadrži čelik, žičanu užad, vlakna aramida, vlakna tekućih kristalnih polimera, vlakna polietilena ultra visoke molekularne težine.
detecting the AB-specific antibodies bound to the AB-aggregates by a single particle detection technique, preferably by fluorescence activated cell sorting (FACS); 
- < otkrivanje AB-specifičnih protutijela vezanih na AB-agregate, pomoću tehnike otkrivanja jedinstvene čestice, poželjno pomoću staničnog razvrstavanja pokrenutog fluorescencijom (FACS).
Hallucinated voices may talk about, or to, the person, and may involve several speakers with distinct personas. 
Halucinirajući glasovi mogu govoriti o osobi ili mogu govoriti osobi te mogu obuhvaćati nekoliko govornika različitih osobnosti.
A shelf-stable dairy mousse according to any one of claims 1 to 7, wherein the shelf-stable dairy mousse has a sugar content of from 5 wt % to 40 wt % with respect to the shelf-stable dairy mousse. 
Mliječna pjena stabilna na sobnoj temperaturi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačena time što mliječna pjena stabilna na sobnoj temperaturi ima sadržaj šećera od 5%, težinski, do 40%, težinski, u odnosu na mliječnu pjenu stabilnu na sobnoj temperaturi.
A pharmaceutical composition according to claim 27 or 28, wherein the sufficient dose of oxycodone is 5 to 400 mg. 
Farmaceutska kompozicija prema patentnom zahtjevu 17 ili 18, naznačena time što je dovoljna doza oksikodona 5 do 400 mg.
A process according to claim 1 wherein said conversion is carried out by reacting a compound of formula IV with dimethylsulfoxonium methylide to give the corresponding keto sulfoxonium ylide of formula which is transformed into a compound of formula II by reaction with an anhydrous halogenhydric acid optionally generated in situ. 
Postupak prema zahtjevu 1 gdje se pretvorba provodi reakcijom spoja formule IV s dimetillsulfoksonij metilidom da se dobije odgovarajući keto sulfoksonij ilid formule F koji se transformira u spoj formule II reakcijom s bezvodnom halogenvodičnom kiselinom po izboru dobivenom in Situ.
The method of claim 14, wherein the composition is administered to pigs having maternally derived antibodies against at least one of M.hyo and PCV2. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se pripravak primjenjuje na praščićima koji imaju majčinska protutijela protiv najmanje jednog od M.hyo i PCV2, ili i M.hyo i PCV2.
when the SAO parameter obtainer obtains SAO type information of the current block from the bitstream, characterized that: 
dobivanje informacije o SAO tipu trenutnog bloka iz toka bitova;
Such adjustment of the length of the chamber in turn alters the pre-load applied to the compression spring. 
Ovakvo podešavanje dužine komore po redu mijenja i prethodno opterećenje na kompresijsku oprugu.
The method of claim 9, wherein at least one accessory molecule is a sugar. 
Postupak sukladno patentnom zahtjevu 1, naznačeno time, da je najmanje jedna aksesorna molekula šećer.
The radical extension of the flange of the bottle is adapted to make a sealing with the inner wall of the housing at the lower surface of the rosette, thus creating a pressure chamber between the inner wall of the housing, the cylindrical wall part of the bottle, and the flange on the shoulder of the bottle. 
Radijalno širenje prirubnice boce prilagođeno je tako da pri donjoj površni rozete nastaje nepropustan spoj s unutarnjom stijenkom kućišta, i tako se stvara tlačna komora između unutarnje stijenke kućišta, cilindrične stijenke dijela boce, i prirubnice na ramenu boce.
a purification step for the biological active compound, wherein the process is conducted in the apparatus according to one of Claims 1 to 17. 
- korak pročišćavanja biološki aktivnog spoja, pri čemu se postupak provodi u uređaju prema jednom od Zahtjeva 1 do 17.
The compound of Paragraph 25, wherein R43 and R44 are, independently, selected from the group consisting of -H, methyl, ethyl, propyl, isopropyl, cyclopropyl, methoxy, ethoxy, propoxy, and cyclopropoxy. Paragraph 33. The compound of Paragraph 25, wherein X42 is CR44; Y40 is CR43; and R43 and R44 together with the carbon atoms to which they are attached form a cycloalkenyl, an aryl, heterocyclyl, or heteroaryl ring. 
Spoj prema zahtjevu 19, pri čemu su R43 1 Ru nezavisno izabrani iz skupine koju čine -H, metil, etil, propil, izopropil i ciklopropil. Spoj prema zahtjevu 19, pri čemu Xpje CR4y; Yao je CRg 1 R43 1 Ra zajedno sa ugljikovim atomima za koje su vezani čine cikloalkenil, aril, heterociklil ili heteroaril prsten.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidene-benzonorbornene-5-yl)amide and as component (B) a compound selected from difenoconazole, propiconazole, cyproconazole and epoxiconazole. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, te kao komponentu (B) fluopiram.
Alternative Method of Preparation of Isomer B and Preparation of Mesylate Salt 3A. 
Alternativni postupak pripreme Izomera B i priprema mesilat soli 3A.
The optical assembly according to claim 1, wherein said secondary reflector elements are selectively orientable individually and/or in groups. 
Optički sklop u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da se navedeni sekundarni reflektorski elementi (31-38) mogu selektivno orijentirati, poželjno pojedinačno i / ili u skupinama.
a polypeptide comprising at least 50 consecutive amino acids selected from SEQ ID NO: 2; 
polipeptid koji sadrži najmanje 50 uzastopnih aminokiselina izabranih iz SEQ ID NO: 2;
The wall mountable electric vehicle charger system according to claim 4, wherein the communication network is the internet. 
Punjač za električna vozila ugradiv na zid (201) u skladu s prethodnim patentnim zahtjevom, naznačen time što je komunikacijska mreža internet.
the antibody, or antigen binding portion thereof, that specifically binds C . difficile toxin B comprises: 
antitijelo ili njegov dio koji se veže za antigen, koje se specifično veže za i neutralizira C. difficile toksin B.
The sail propulsion system according to claim 1, wherein, when the boat sails close to the wind, the jib (F) and the leeward mainsail (RS, RD) are slightly overlapped. 
Porivni sustav za jedrenje prema zahtjevu 1, naznačen time što kada čamac ili slično plovilo jedri blizu vjetra, prednje jedro (F) i zavjetrinsko glavno jedro (RS, RD) se lagano preklapaju.
A non-naturally occurring and/or purified and/or engineered nucleic acid encoding the TCR of claim 1 . 
Nukleinska kiselina koja ne postoji u prirodi i/ili je pročišćena i/ili konstruirana, koja kodira TCR sukladno bilo kojem od prethodnih patentnih zahtjeva.
The pharmaceutical composition or package for use according to claim 7, wherein the amount of glatiramer acetate is 300 mg/week. 
Farmaceutski sastav ili pakiranje za uporabu u skladu s patentnim zahtjevom 7, naznačeni time, da količina glatiramer acetata jest 300 mg/tjedno.
After two weeks of acclimation, animals (7 weeks of age) are bled on day 0 at 1000-1200h (lights on 0600h) and assigned to treatment groups (n = 5 or 6) based on starting glucose values. Compound or vehicle only treatments are administered daily by oral gavage at approximately 0730h. 
Nakon dva tjedna privikavanja, životinjama (starim 7 tjedana) je 0. dana uzeta krv u 10:00 do 12:00 sati (svjetla se pale u 06:00 sati), te su raspodijeljeni u skupine za obradu (n = 5 ili 6), na osnovu polaznih vrijednosti glukoze.
Numbered Embodiment 2 A composition according to numbered embodiment 1, wherein the components a), b) and c) comprise substantially the entire composition. 
Postupak prema zahtjevu 1, naznačen time da komponente a), b) i c) u većoj mjeri čine cijelu rashladnu tvar.
The method according to claim 1 wherein the pathological conditions where oxidative stress causes or results in pathogenesis is selected from the group consisting of allergies, stroke, Alzheimer's disease, and ischemic cardiovascular disease. 
Upotreba prema bilo kojem zahtjevu 18 do 31, naznačena time, da su patološka stanja u čijoj patogenezi ima važnu ulogu oksidativan stres odabrana iz skupine koju čine alergije, udar kapi, Alzheimerova bolest 1 ishemijske kardiovaskularne bolesti.
The method of claim 9, wherein said monomers are linked to each other through a multifunctional PEG. 
Oligomer prema zahtjevu 4, naznačen time da mnoštvo monomera ima slobodne cisteine i međusobno su vezani preko bis-maleimidih PEG-ova.
The method of claim 1 including directing at least a portion of the dewatered sludge around the heat exchanger and to the hydrolysis reactor without the dewatered sludge passing through the heat exchanger. 
Postupak prema patentnom zahtjevu 1 naznačeno time da se dio odvodnjenog mulja usmjerava oko izmjenjivača topline (216) i prema reaktoru za hidrolizu (214) bez da odvodnjeni mulj prolazi kroz izmjenjivač topline.
A method for making a humanized rodent, comprising replacing a genomic DNA of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a human genomic DNA of a human IL-4Ra gene to form a humanized IL-4Ra gene, wherein the genomic DNA of the rodent IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the rodent IL-4Ra gene, and the human genomic DNA of the human IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene; wherein the humanized IL-4Ra gene comprises the ATG initiation codon of exon 1 through exon 5 of the human IL-4Ra gene followed by exons 6-9 of the rodent IL-4Ra gene, and the human genomic DNA present in the humanized IL-4Ra gene begins with the ATG initiation codon of exon 1 of the human IL-4Ra gene; and wherein the humanized IL-4Ra gene is operably linked to the rodent IL-4Ra promoter at the endogenous rodent IL-4Ra locus, wherein the rodent is a mouse or a rat. 
Glodavac u skladu s bilo kojim od patentnih zahtjeva 1-2, 4 1 6, naznačen time što je miš. Postupak dobivanja humaniziranog glodavca, naznačen time što se sastoji u zamjeni genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra. genomskim fragmentom gena za ljudski IL-4Ra kako bi se dobilo gen za humanizirani IL-4Ra. koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ro, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra. sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni gen ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, gdje je gen za humanizirani IL-4Ro. operativno povezan s regulacijskim elementim glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
The composition of claim 25, further comprising administering concurrently an additional anti-hepatitis C virus agent. 
Pripravak u skladu s patentnim zahtjevom 25, naznačen time, da nadalje sadrži istodobnu primjenu dodatnog sredstva protiv virusa hepatitisa C.
The compound for the use according to claim 1, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, melanoma, sarcoma, liver cancer, brain tumors, multiple myeloma, and leukemia. 42118961v.1 
Kombinacija iz patentnog zahtjeva 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma glave 1 vrata, karcinoma pluća, karcinoma jajnika, karcinoma gušterače, kolorektalnog karcinoma, karcinoma prostate, karcinoma stanica bubrega, melanoma, hepatocelularnog karcinoma, karcinoma cerviksa, sarkoma, tumora na mozgu, karcinoma želuca, multiplog mijeloma, leukemije i limfoma.
• compressing the dry blend into a solid dosage unit. 
* komprimiranje suhe mješavine u čvrstu doznu jedinicu.